



## Revista Brasileira de Hematologia e Hemoterapia Brazilian Journal of Hematology and Hemotherapy

www.rbhh.org



### Letter to the Editor

## Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms



Dear Editor,

Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) are Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) characterized by increased myeloid proliferation. The gain of function induced by the *Janus kinase 2* mutation,  $JAK2^{V617F}$ , has been reported in most PV and in more than half of ET and PMF cases.<sup>1</sup> However, the presence of different disease phenotypes and the absence of the  $JAK2$  mutation in some MPNs suggests that additional genetic lesions or/and aberrant signaling pathways may be involved in the pathogenesis of these diseases.<sup>1,2</sup>

In December 2013, somatic mutations in the *calreticulin* (*CALR*) gene were identified in ET and PMF patients by two independent groups<sup>3,4</sup> and confirmed by others.<sup>5–9</sup> *CALR* mutations have been reported as mutually exclusive with  $JAK2$  and *MPL* mutations and may be present in 56–88% of  $JAK2$ /*MPL*-negative cases.<sup>3,4</sup> A recent paper reported a patient that had both mutations,  $JAK2^{V617F}$  and a *CALR* exon 9 mutation, simultaneously.<sup>10</sup> Over thirty different *CALR* mutations in exon 9 have been described, but the most frequent mutations (about 80%) may be classified as type-1 [L367fs\*46; deletion of 52 base pairs (bp)] and type-2 (K385fs\*47; insertion of 5 bp).<sup>3,4</sup> The functional changes induced by the mutations are still not completely elucidated, but the overexpression of the type 1 *CALR* mutation in Ba/F3 cells (an IL3 dependent cell line) leads to cytokine-independent cell growth and STAT5 activation.<sup>4</sup> Gene expression signature studies also indicate that  $JAK2$  and *CALR* mutations share mechanisms of malignant transformation, reaffirming a central role of the *JAK*/*STAT* signaling pathway in the pathogenesis of MPN.<sup>11</sup>

The aim of the present study was to characterize the prevalence of *CALR* mutations and the clinical and laboratorial characteristics of *CALR*-mutated patients in a Brazilian cohort of MPNs. Seventy-three MPN patients were included in the study (ET = 32, PV = 20, PMF = 21). Patients' characteristics are described in Table 1. Peripheral blood samples were collected, submitted to hemolysis, and DNA was extracted by the

phenol/chloroform method. All samples were investigated for  $JAK2$  and *CALR* mutations. The  $JAK2^{V617F}$  mutation and *CALR* exon 9 mutations were verified as previously described.<sup>12,13</sup> *CALR* mutations were classified as type-1 (deletion of 52 bp), type-2 (insertion of 5 bp) or others (Figure 1).


In our cohort, *CALR* mutations were found in 20 patients (13 ET and 7 PMF; Table 1) and were mutually exclusive with  $JAK2^{V617F}$ : 20/73 (27%) of total MPN patients and 20/28 (71%) of the  $JAK2^{WT}$  patients. Among the *CALR*-mutated patients, Type-1 *CALR* mutations were found in 50% (10/20; 8 ET and 2 PMF), type-2 in 40% (8/20; 4 ET and 4 PMF), and others in 10% (1 ET and 1 PMF) of the individuals. *CALR* mutations were not detected in PV patients (all  $JAK2^{V617F}$  positive). In ET, *CALR*<sup>MUT</sup> patients showed reduced hemoglobin levels compared with  $JAK2^{V617F}$  patients (*p*-value <0.01; Table 2); no differences were observed in white blood cell, neutrophil and platelet counts, thrombotic events, hepatomegaly, splenomegaly and constitutional symptoms. In PMF patients, *CALR* mutational status was not associated with clinical features (Table 2). The frequency of *CALR* mutations in this Brazilian cohort was similar to previously described frequencies.<sup>3,4,7</sup> Furthermore, *CALR* and  $JAK2^{V617F}$  mutations were mutually exclusive. Knowledge regarding the clinical impact of *CALR* mutations in MPNs is still under construction, but some studies indicate that *CALR*-mutated patients have lower ages at disease onset, lower hemoglobin and platelet counts, and have better overall survival than either  $JAK2$ -mutated or *CALR*/ $JAK2$ /*MPL* wild-type patients.<sup>5,9,14</sup> In our cohort, *CALR*<sup>MUT</sup> ET patients presented lower hemoglobin levels, compared with  $JAK2^{V617F}$  ET patients, even though in both groups hemoglobin values remained within the reference range.

In conclusion, *CALR* mutations are highly frequent in Brazilian patients with MPN. The search for *CALR* mutations may be a useful tool for MPN diagnosis and further research on this mutation in Brazilian patients would be important to define the local incidence of the mutation, to improve diagnosis and classification of our patients, and to better evaluate the impact of these mutations on the outcomes of MPN patients.

**Table 1 – Patient characteristics.**

|                                                                  | MPN (n = 73)    | ET (n = 32)    | PV (n = 20)      | PMF (n = 21)    |
|------------------------------------------------------------------|-----------------|----------------|------------------|-----------------|
| Age (years) – median (range):                                    | 57 (19–87)      | 53 (19–83)     | 70 (41–88)       | 62 (27–87)      |
| Gender – male/female                                             | 30/43           | 10/22          | 9/11             | 11/10           |
| Hemoglobin (g/dL) – median (range)                               | 13.9 (8.1–22.7) | 13.6 (9.7–17)  | 18.4 (12.8–22.7) | 12.5 (8.1–19.9) |
| WBC count ( $\times 10^9 \text{ L}^{-1}$ ) – median (range)      | 9.8 (2.4–43.2)  | 9 (3.0–17.8)   | 11.2 (6.3–25.5)  | 11.8 (2.4–43.2) |
| Platelet count ( $\times 10^9 \text{ L}^{-1}$ ) – median (range) | 764 (108–2065)  | 914 (541–2065) | 609 (203–1070)   | 661 (108–1716)  |
| JAK2 mutation status – n (%)                                     |                 |                |                  |                 |
| JAK2 <sup>WT</sup>                                               | 28 (38)         | 20 (63)        | 0 (0)            | 8 (38)          |
| JAK2 <sup>V617F</sup>                                            | 45 (62)         | 12 (37)        | 20 (100)         | 13 (62)         |
| CALR mutation status – n (%)                                     |                 |                |                  |                 |
| CALR <sup>WT</sup>                                               | 53 (73)         | 19 (59)        | 20 (100)         | 14 (67)         |
| CALR <sup>MUT</sup>                                              | 20 (27)         | 13 (41)        | 0 (0)            | 7 (33)          |

MPN: myeloproliferative neoplasms; ET: essential thrombocythemia; PV: polycythemia vera; PMF: primary myelofibrosis; WBC: white blood cell count; JAK2: Janus kinase 2 gene; WT: wild-type; CALR: Calreticulin gene; MUT: exon 9 mutations.



**Figure 1 – Calreticulin (CALR) indel mutations in myeloproliferative neoplasm (MPN) patients. (A)** PCR amplification of exon 9 of CALR gene loaded on 4% agarose gel; lane 1: 100 bp marker (M); lane 2: no template control (NTC); MPN patients #1 and #2: CALR<sup>WT</sup>; #3 and #4: heterozygotes for type-1 CALR mutation (CALR<sup>WT</sup> amplicons: 297 bp; type-1 CALR<sup>MUT</sup> amplicons: 245 bp); #5 and #6: heterozygotes for type-2 CALR mutation (CALR<sup>WT</sup> amplicons: 297; type-2 CALR<sup>MUT</sup> amplicons: 302 bp); #7: heterozygote for non-type-1 or -2 CALR mutation (CALR<sup>WT</sup> amplicons: 297 bp; CALR<sup>MUT</sup> amplicons: 291 bp). **(B)** Representative PCR fragment size analysis of CALR amplicons from MPN patients: the orange peaks represent the GeneScan 500 LIZ dye Size Standard and blue peaks represent the CALR amplicons; the black arrows indicate the wild-type allele (297 bp) and the red arrows indicate the indel-mutation alleles.

**Table 2 – Clinical and laboratory features of essential thrombocythemia and primary myelofibrosis patients, stratified according to JAK2 and CALR mutational status.**

|                                                  | Essential thrombocythemia |                       |                                        |                        | Primary myelofibrosis <sup>b</sup> |                     |                       |                        |
|--------------------------------------------------|---------------------------|-----------------------|----------------------------------------|------------------------|------------------------------------|---------------------|-----------------------|------------------------|
|                                                  | CALR <sup>MUT</sup>       | JAK2 <sup>V617F</sup> | CALR <sup>WT</sup> /JAK2 <sup>WT</sup> | p-value <sup>a,c</sup> | p-value <sup>a,d</sup>             | CALR <sup>MUT</sup> | JAK2 <sup>V617F</sup> | p-value <sup>a,c</sup> |
| Gender: male/female – n (%)                      | 4 (31)/9 (69)             | 5 (42)/7 (58)         | 1 (14)/6 (86)                          | 0.69                   | 0.61                               | 4 (57)/3 (43)       | 6 (46)/7 (54)         | 1.00                   |
| Age – years (range)                              | 57 (20–82)                | 55 (44–83)            | 43 (19–53)                             | 0.61                   | 0.13                               | 53 (27–80)          | 65 (43–87)            | 0.30                   |
| Hemoglobin – g/L (range)                         | 13 (10–15)                | 14 (12–17)            | 14 (12–16)                             | 0.007                  | 0.12                               | 12 (9–13)           | 14 (8–20)             | 0.08                   |
| White blood cells – $\times 10^9 L^{-1}$ (range) | 7.1 (3–17.8)              | 9.2 (4.5–16.7)        | 9 (5–11.8)                             | 0.64                   | 0.69                               | 9.4 (2.4–35.7)      | 11.8 (8.4–43.2)       | 0.38                   |
| Neutrophils – $\times 10^9/L$ (range)            | 4.8 (2.1–15.1)            | 6 (2.5–12)            | 5.6 (3.2–8.5)                          | 0.43                   | 0.48                               | 6.2 (1–22.5)        | 7.1 (0.5–38.3)        | 0.48                   |
| Platelets – $\times 10^9/L$ (range)              | 938 (593–2065)            | 880 (541–1340)        | 984 (617–1274)                         | 0.37                   | 0.87                               | 567 (108–1716)      | 661 (129–1606)        | 0.69                   |
| Thrombotic events – n (%)                        | 0 (0)                     | 2 (17)                | 0 (0)                                  | 0.50                   | 1.00                               | 0 (0)               | 1 (8)                 | 1.00                   |
| Hepatomegaly – n (%)                             | 1 (8)                     | 0 (0)                 | 0 (0)                                  | 1.00                   | 1.00                               | 0 (0)               | 2 (17)                | 1.00                   |
| Splenomegaly – n (%)                             | 2 (15)                    | 1 (8)                 | 1 (14)                                 | 1.00                   | 1.00                               | 5 (71)              | 7 (54)                | 0.64                   |
| Constitutional symptoms – n (%)                  | 1 (8)                     | 3 (25)                | 2 (29)                                 | 0.32                   | 0.27                               | 1 (14)              | 3 (23)                | 1.00                   |

<sup>a</sup> Fisher's exact test was used for categorical factors with 2 levels; Mann-Whitney test for measured factors.<sup>b</sup> Only one patient with primary myelofibrosis presented CALR<sup>WT</sup>/JAK2<sup>WT</sup>.<sup>c</sup> CALR<sup>MUT</sup> vs. JAK2<sup>V617F</sup>.<sup>d</sup> CALR<sup>MUT</sup> vs. CALR<sup>WT</sup>/JAK2<sup>WT</sup>.

## Conflicts of interest

The authors declare no conflicts of interest.

## REFERENCES

- Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet*. 2005;365(9464):1054–61.
- Thoenissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. *Blood*. 2010;115(14):2882–90.
- Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. *N Engl J Med*. 2013;369(25):2391–405.
- Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med*. 2013;369(25):2379–90.
- Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. *Leukemia*. 2014;28(7):1472–7.
- Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. *Blood*. 2014;123(10):1552–5.
- Wu Z, Zhang X, Xu X, Chen Y, Hu T, Kang Z, et al. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. *J Hematol Oncol*. 2014;7:48.
- Shen H, Chao H, Ding Z, Feng Y, Cen J, Pan J, et al. CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia. *Leuk Lymphoma*. 2014;1–9.
- Li B, Xu J, Wang J, Gale RP, Xu Z, Cui Y, et al. Calreticulin mutations in Chinese with primary myelofibrosis. *Haematologica*. 2014;99(11):1697–700.
- McGaffin G, Harper K, Stirling D, McLintock L. JAK2 V617 F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. *Br J Haematol*. 2014;167(2):276–8.
- Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. *Blood*. 2014;123(22):e123–33.
- da Silva RR, Domingues Hatzlhofer BL, Machado CG, Lima AS, de Albuquerque DM, dos Santos MN, et al. JAK2 V617 F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil. *Genet Test Mol Biomarkers*. 2012;16(7):802–5.
- Chi J, Nicolaou KA, Nicolaidou V, Koumas L, Mitsidou A, Pierides C, et al. Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. *Leukemia*. 2014;28(5):1152–4.
- Chen CC, Gau JP, Chou HJ, You JY, Huang CE, Chen YY, et al. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. *Ann Hematol*. 2014;93(12):2029–36.

João Agostinho Machado-Neto<sup>1</sup>, Paula de Melo Campos<sup>1</sup>,  
Dulcinéia Martins de Albuquerque, Fernando Ferreira Costa,  
Irene Lorand-Metze, Sara Terezinha Olalla Saad,  
Fabiola Traina\*

*Universidade Estadual de Campinas (UNICAMP), Campinas, SP,  
Brazil*

\*Corresponding author at: Rua Carlos Chagas, 480, 13083-878  
Campinas, SP, Brazil.

E-mail addresses: [ftraina@fmrp.usp.br](mailto:ftraina@fmrp.usp.br),  
[fbiolatraina@gmail.com](mailto:fbiolatraina@gmail.com) (F. Traina).

<sup>1</sup> Both authors contributed equally to this work.

Received 19 September 2014

Accepted 25 February 2015

Available online 15 April 2015

<http://dx.doi.org/10.1016/j.bjhh.2015.03.012>

1516-8484/© 2015 Associação Brasileira de Hematologia,  
Hemoterapia e Terapia Celular. Published by Elsevier Editora  
Ltda. All rights reserved.